Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
$15.71
-2.3%
$16.41
$12.72
$34.47
$2.69B0.661.37 million shs1.53 million shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$42.96
-1.8%
$43.85
$19.44
$53.27
$2.80B2.18576,681 shs393,426 shs
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$49.96
+3.0%
$58.32
$47.04
$103.81
$2.76B1.051.19 million shs1.28 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%-7.32%-6.51%+3.22%-43.63%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
0.00%-6.18%-4.13%+27.93%+2.19%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
0.00%-10.34%-15.32%-8.18%-12.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
1.6064 of 5 stars
3.40.00.00.03.11.70.0
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.5645 of 5 stars
4.63.00.00.03.42.50.0
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.531 of 5 stars
3.41.00.00.03.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00
N/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
2.82
Moderate Buy$36.40131.70% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.10
Buy$59.1137.60% Upside
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
2.78
Moderate Buy$84.1368.38% Upside

Current Analyst Ratings Breakdown

Latest CNVY, IMVT, PRCT, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$60.00
7/28/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$17.00 ➝ $18.00
7/15/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/15/2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $68.00
7/10/2025
Immunovant, Inc. stock logo
IMVT
Immunovant
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$18.00
7/9/2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
7/7/2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform
7/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$70.00
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
(Data available from 8/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$337.60M2.28$0.46 per share22.90$7.35 per share1.43
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.16 per shareN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M59.43N/AN/A$12.90 per share3.33
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
$224.50M12.31N/AN/A$7.71 per share6.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
-$9.98M-$0.10N/A25.63N/A-1.90%0.08%0.05%N/A
Immunovant, Inc. stock logo
IMVT
Immunovant
-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$91.41M-$1.70N/AN/AN/A-36.20%-28.09%-20.02%8/6/2025 (Estimated)

Latest CNVY, IMVT, PRCT, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.84N/AN/AN/A$17.37 millionN/A
8/6/2025Q2 2025
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
-$0.41N/AN/AN/A$75.67 millionN/A
8/5/2025Q1 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.69N/AN/AN/AN/AN/A
5/29/2025Q4 2025
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.72-$0.64+$0.08-$0.64N/A$0.16 million
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.50
2.20
1.60
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
11.16
11.16
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
0.13
8.95
7.75

Institutional Ownership

CompanyInstitutional Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
85.28%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
89.46%

Insider Ownership

CompanyInsider Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
6.20%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.80%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
16.01%
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
17.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
3,80073.19 million68.66 millionNot Optionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120171.07 million167.99 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
PROCEPT BioRobotics Corporation stock logo
PRCT
PROCEPT BioRobotics
43055.33 million45.70 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Convey Health Solutions stock logo

Convey Health Solutions NYSE:CNVY

Convey Health Solutions Holdings, Inc. provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company also offers health plan management, data analytics, supplemental benefit, advisory, and software services. The Advisory Services segment offers sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. It serves government sponsored, medicare advantage, medicare, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Health Solutions Holdings, Inc. is a former subsidiary of TPG Cannes Aggregation, L.P.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$15.71 -0.37 (-2.30%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$15.55 -0.16 (-1.02%)
As of 08/1/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$42.96 -0.79 (-1.81%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$42.92 -0.04 (-0.09%)
As of 08/1/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

PROCEPT BioRobotics stock logo

PROCEPT BioRobotics NASDAQ:PRCT

$49.96 +1.45 (+2.99%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$50.94 +0.98 (+1.96%)
As of 08/1/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.